Exacerbation Rates and Healthcare Resource Utilization (HRU) in Asthma Patients Initiating Tiotropium Respimat (Tio-RMT)
نویسندگان
چکیده
منابع مشابه
Tiotropium Bromide/Olodaterol (Stiolto Respimat)
INTRODUCTION Chronic obstructive pulmonary disease (COPD), a relatively common respiratory disorder in the U.S., is the third leading cause of death in this country.1 It has been estimated that 15 million Americans have COPD.1 Since the disorder is so common, effective treatment regimens are a prominent research topic in pharmacology. Still, the development of pharmacological treatments for COP...
متن کاملTiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma
BACKGROUND Tiotropium, a once-daily long-acting anticholinergic bronchodilator, when administered via Respimat® SoftMist™ inhaler (tiotropium Respimat®) significantly reduces the risk of severe exacerbations and improves lung function in patients with severe persistent asthma that is not fully controlled despite using inhaled corticosteroids (ICS) and long-acting β2-agonists. To further explore...
متن کاملHealthcare utilization and costs for patients initiating Dabigatran or Warfarin
BACKGROUND Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource utilization (HCRU) and similar total costs. This study expands on previous work by comparing HCRU and costs for patients newly diagnosed with NVAF and n...
متن کاملHealthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting
INTRODUCTION Inadequately controlled asthma is associated with increased healthcare resource utilization. The eXpeRience registry was initiated to evaluate real-world outcomes in patients receiving omalizumab for uncontrolled persistent allergic asthma. The current analysis of data from the eXpeRience registry focuses on healthcare resource utilization and on absences from work or school. MET...
متن کاملTiotropium Respimat increases the risk of mortality.
In the 10 years since tiotropium was introduced into clinical practice, it has become the mainstay long-acting bronchodilator for maintenance treatment in Chronic Obstructive Pulmonary Disease (COPD). Multiple randomised controlled trials have demonstrated its efficacy as an intervention which improves lung function, quality of life, symptom control and exercise capacity, and reduces exacerbati...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Allergy and Clinical Immunology
سال: 2020
ISSN: 0091-6749
DOI: 10.1016/j.jaci.2019.12.878